GERIATRICS & GERONTOLOGY INTERNATIONAL, cilt.15, sa.6, ss.729-735, 2015 (SCI-Expanded)
AimsWe aimed to investigate whether older age leads to limitations in the starting dose of imatinib in daily treatment of chronic myeloid leukemia, and to determine the compliance of elderly patients with tyrosine kinase inhibitors (TKI) therapy.